HOB Biotech Group Corp.,Ltd

Shanghai Stock Exchange 688656.SS

HOB Biotech Group Corp.,Ltd Debt to Equity Ratio for the year ending December 31, 2023: 0.06

HOB Biotech Group Corp.,Ltd Debt to Equity Ratio is 0.06 for the year ending December 31, 2023, a -24.97% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

HOB Biotech Group Corp.,Ltd Debt to Equity Ratio for the year ending December 31, 2022 was 0.08, a 109.31% change year over year.
HOB Biotech Group Corp.,Ltd Debt to Equity Ratio for the year ending December 31, 2021 was 0.04, a -81.19% change year over year.
HOB Biotech Group Corp.,Ltd Debt to Equity Ratio for the year ending December 31, 2020 was 0.21, a -36.29% change year over year.
HOB Biotech Group Corp.,Ltd Debt to Equity Ratio for the year ending December 31, 2019 was 0.33, a 134.14% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shanghai Stock Exchange: 688656.SS

HOB Biotech Group Corp.,Ltd

CEO	Mr. John Li
IPO Date	Jan. 13, 2021
Location	China
Headquarters	C10 Building
Employees	550
Sector	Healthcare
Industries Biotechnology 3D Printing Cleaning Supplies Clinical Trials Medical Instruments Personal Care Pharmaceuticals Vaccines

Description

HOB Biotech Group Corp.,Ltd. operates as a in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immuno assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company was founded in 2009 and is based in Suzhou, China.

Key trends

Past 5 years